Oxidative stress in hypertensive children before and after 1 year of antihypertensive therapy.
BACKGROUND
The relation between primary hypertension (PH), target organ damage (TOD) and oxidative stress (SOX) is not known.


METHODS
We assessed SOX in 86 children with PH before and after 12 months of standard non-pharmacological and pharmacological therapy based on renin-angiotensin system blockade.


RESULTS
Patients with left ventricular hypertrophy (LVH) and with carotid intima-media thickness (cIMT) >2SDS had higher thiobarbituric acid reactive substances (TBARS) concentrations in comparison to patients without LVH or with normal cIMT. Patients with metabolic syndrome (MS) had lower activity of gluthatione peroxidase, higher asymmetric dimethyloarginine (ADMA) and oxidized LDL cholesterol (oxyLDL) in comparison to patients without MS. TBARS correlated with left ventricular concentric hypertrophy, cIMT, albuminuria and SBP/24 h. ADMA and oxyLDL correlated with CRP and TG/HDL ratio. After 1 year of antihypertensive treatment blood pressure, TOD and prevalence of MS decreased. TBARS decreased and glutathione concentrations increased. The decrease of TBARS concentration correlated with the decrease of body mass index (BMI). Decrease of oxyLDL and ADMA correlated with increased insulin sensitivity, however markers of SOX did not correlate with BP decrease.


CONCLUSIONS
SOX in children with PH correlates with TOD, metabolic abnormalities, changes in fat amount and improvement of insulin sensitivity, but not with BP decrease.
Department of Nephrology and Arterial Hypertension, The Children's Memorial Health Institute, Warsaw, Poland.
Joanna
J
Sladowska-Kozłowska
Mieczysław
M
Litwin
Anna
A
Niemirska
Paweł
P
Płudowski
Aldona
A
Wierzbicka
Ewa
E
Skorupa
Zbigniew T
ZT
Wawer
Roman
R
Janas
D050154:Adiposity; D000293:Adolescent; D000419:Albuminuria / Q000097:blood / Q000209:etiology; D000704:Analysis of Variance; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives / Q000097:blood; D015415:Biomarkers / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002097:C-Reactive Protein / Q000378:metabolism; D002340:Carotid Artery Diseases / Q000097:blood / Q000209:etiology / Q000473:pathology; D059168:Carotid Intima-Media Thickness; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D005979:Glutathione Peroxidase / Q000097:blood; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology; D007333:Insulin Resistance; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications / Q000503:physiopathology; D018384:Oxidative Stress / Q000187:drug effects*; D011044:Poland; D012720:Severity of Illness Index; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D015415:Biomarkers; D008078:Cholesterol, LDL; D008077:Lipoproteins, LDL; D017392:Thiobarbituric Acid Reactive Substances; C099252:oxidized low density lipoprotein; C018524:N,N-dimethylarginine; D002097:C-Reactive Protein; D001120:Arginine; D005979:Glutathione Peroxidase